Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06841913 · ClinicalTrials.gov registry record · Phase 4
Woodsmoke Exposure, Influenza Infection, and Nasal Immunity
A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 112
- Enrollment target
NCT06841913: Recruiting Phase 4 study, sponsored by University of North Carolina, Chapel Hill.
NCT06841913 is a Phase 4 study that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 112 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06841913, a Phase 4 study, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 112 participants
- Enrollment target
Study Summary
This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symptoms, and reduces mucosal antibody production.
Primary Outcome
Analysis of the nasal mucosal secretome (secreted factors identified as responsive to WS and/or LAIV). Area under the curve (AUC) will be calculated for each proteomic profile. Descriptive statistics (means and standard deviations) will be computed for outcomes of interest (AUCs), assuming normal distribution as in previous studies.
Interventions
- BIOLOGICAL LAIV nasal vaccine is chosen as a model viral infection
- OTHER Wood smoke
- BIOLOGICAL Placebo for LAIV nasal vaccine is chosen as a model viral infection
- OTHER Placebo for Wood Smoke (clean Air Exposure)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2025-09-26 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 4 |
What NCT06841913 shows while recruiting
NCT06841913 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (78% lower).
The record links to 0 conditions, and to 4 interventions - of which LAIV nasal vaccine is chosen as a model viral infection is the first listed.
NCT06841913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06841913 about?
NCT06841913 is a clinical study titled "Woodsmoke Exposure, Influenza Infection, and Nasal Immunity". This study will investigate the effects of woodsmoke (WS) exposure on human nasal mucosal immune responses to viral infection. The study tests the hypotheses that WS exposure modifies biomarkers of nasal mucosal immune function, increases in Live Attenuated Influenza Virus (LAIV) -induced nasal symp...
What is the current status of trial NCT06841913?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 112 participants. The study started on 2025-09-26. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT06841913?
The interventions under investigation include: LAIV nasal vaccine is chosen as a model viral infection (BIOLOGICAL), Wood smoke (OTHER), Placebo for LAIV nasal vaccine is chosen as a model viral infection (BIOLOGICAL), Placebo for Wood Smoke (clean Air Exposure) (OTHER).
Who is sponsoring clinical trial NCT06841913?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06841913's enrollment target sits among peer trials
112 724th of 2000 higher than 1,275 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI